Topos Bio

San Francisco, California, United States

Topos Bio is a healthcare startup focused on redefining the drug discovery process for intrinsically disordered proteins (IDPs) through an AI-native platform. Founded by researchers from Berkeley and Stanford, the company has released its first technical report on Topos-1, an all-atom foundation model specifically designed to generate physically realistic conformational ensembles for flexible proteins, allowing for practical ensemble-level modeling in research and drug discovery. With a recent funding of $10.5 million, Topos aims to tackle "undruggable" protein targets implicated in diseases such as Alzheimer's and prostate cancer, while partnering with organizations like the Gladstone Institutes to enhance its capabilities.